This distinguishes retatrutide from GLP-1 receptor agonists such as semaglutide, which primarily target the GLP-1 receptor, and dual agonists such as tirzepatide, which act on GLP-1 and GIP receptors without activating the glucagon receptor.[3] This three-receptor profile is a major reason retatrutide has drawn interest in metabolic research
Thus, it is not surprising that GSH (or the [GSH]/[GSSG] ratio) plays a key role in many diseases including cancer, inflammation, Alzheimer's disease, Parkinson's disease, sickle cell anemia, liver disease, cystic fibrosis, AIDS, heart attack, stroke, and diabetes [4, 6] as well as in aging [79]
If youre unsure how to move forward, or if youre noticing hunger returning, weight fluctuations, or anxiety about stopping
People with active cancer should consult their healthcare provider before using GHK-Cu because the peptide promotes angiogenesis, which could theoretically supply blood to tumors